CAJ | 학술논문

目的探讨培美曲赛联合奈达铂治疗晚期肺腺癌的疗效及毒副作用。方法收集48例经病理组织学或细胞学确诊的晚期肺腺癌患者，接受培美曲赛联合奈达铂方案化疗：培美曲赛500mg/㎡ d1静点，奈达铂85mg/㎡，d2或d2-5静点。每例患者均治疗2周期以上，观察疗效及毒副反应。结果48例患者均可评价疗效，获得PR 11例，SD 19例，PD18例，有效率为22.9%（11/48），疾病控制率为62.5%(30/48)，中位无进展生存期为10.3个月，主要毒副作用包括骨髓抑制、胃肠道反应、乏力和周围神经毒性，以I-II度为主。结论培美曲赛联合奈达铂方案治疗晚期肺腺癌疗效确切，毒副反应发生率较低，耐受性好。
목적탐토배미곡새연합내체박치료만기폐선암적료효급독부작용。방법수집48례경병리조직학혹세포학학진적만기폐선암환자，접수배미곡새연합내체박방안화료：배미곡새500mg/㎡ d1정점，내체박85mg/㎡，d2혹d2-5정점。매례환자균치료2주기이상，관찰료효급독부반응。결과48례환자균가평개료효，획득PR 11례，SD 19례，PD18례，유효솔위22.9%（11/48），질병공제솔위62.5%(30/48)，중위무진전생존기위10.3개월，주요독부작용포괄골수억제、위장도반응、핍력화주위신경독성，이I-II도위주。결론배미곡새연합내체박방안치료만기폐선암료효학절，독부반응발생솔교저，내수성호。
Objective: To observe the efficacy and adverse reaction of pemetrexed combined with nedaplatin in the treatment of patients with advanced lung adenocarcinoma. Methods:48 advanced stage adenocarcinoma patients were final y confirmed by pathohistological or cytological examination.500mg/㎡Pemetrexed was mixed with 100ml normal saline which was then dripped IV on the first day; And 85mg/㎡Nedaplatin was mixed with 500 ml normal saline which was then dripped IV on the second or second to fifth day,with 21 day being a cycle. The efficacy and toxic reaction were evaluated after at least 2 cycles. Results: Al the 48 patients had completed a total of 142 treatment cycles,the efficacy evaluation could be conducted in everyone of them,in which there were 11 cases of PR,19 cases of SD,and 18 cases of PD,while the objective response rate(RR)reached 22.9%(11/48), the disease control rate(DCR) reached 62.5%(30/48),and the PFS was 10.3 months.Major adverse effects were myelosuppression,lassitude and gastrointestinal tract reactions,most of which were I-I degree degree.Conclusion: Pemetrexed combination with Nedaplatin provide advanced lung adenocarcinoma patients with good curative effect, quality of life, and adverse effect are tolerable.